News | November 15, 2010

Registry Created to Test Effectiveness of CTA

November 15, 2010 – The registry for a study designed to test the effectiveness of coronary computed tomographic angiography (CCTA) for diagnosing coronary artery disease (CAD) was announced at the American Heart Association (AHA) Scientific Session. The CONFIRM study spans six countries and will look at more than 27,000 patients.

Though the 2010 Expert Consensus on CCTA declared the evidence base “sufficiently mature” for clinical practice guidelines, CONFIRM addresses several gap areas.

“The international multicenter CONFIRM registry of more than 27,000 patients represents a highly collaborative effort of investigators at more than 12 centers who are examining the prognostic significance of coronary CT angiography findings,” said James K. Min, M.D., professor of medicine and radiology at the Cornell University Medical Center/New York Presbyterian Hospital and lead investigator of the CONFIRM registry. “The CONFIRM data definitively establish the prognostic value of CT-identified coronary artery disease and the risk of death associated with these findings. We hope that the CONFIRM data will allow for earlier detection of patients at risk for adverse coronary artery disease-related events and will result in improved treatment and outcomes of patients with coronary artery disease.”

There is a strong expectation that more long-term studies will be carried out in the future.

“CONFIRM is an important step in the validation of cardiac CT angiography,” said Matthew J. Budoff, M.D., FSCCCT, professor of medicine at the David Geffen School of Medicine at UCLA, director of cardiac CT at Los Angeles Biomedical Research Center at Harbor UCLA Medical Center and president of the Society of Cardiovascular Computed Tomography. “The size and scope of the project, coupled with the robust findings, should raise physician confidence that CT has an established role in clinical medicine.”

For more information: www.americanheart.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now